Is Zoom's profit rise set to slow?
Zoom, the videoconferencing company, has produced an extraordinary surge in profits and sales. Can it keep up the momentum? Matthew Partridge reports


Thanks to “blowout earnings” – more than double the expected total – in its second quarter, Zoom’s shares have hit a record high, says Kari Paul in The Guardian. The company is now worth more than $100m. Sales rose by 355% year-on-year to $663.5m in the three months to 1 August, also eclipsing analysts’ estimates. Despite facing “intense criticism” over privacy, the videoconferencing company has benefited from a huge jump in users as countries have locked down. Zoom has become “nearly synonymous” with video hangouts. It is used for happy hours, teaching in schools and events.
Zoom may have surpassed expectations, but its management certainly doesn’t think that this is a one-off, says Nico Grant on Bloomberg. The company predicts that the “explosive growth” will continue, with overall sales of $2.4bn in the fiscal year that ends next January, implying that revenue “would almost quadruple in just one year”. It is also confident that this period of “hyper growth” will last beyond the peak of Covid-19, with any churn from users cancelling their accounts as restrictions ease “manageable”.
A tailwind for software
Zoom’s rise has also been powered by the boom in “software as service”, says James Titcomb in The Sunday Telegraph. This is where companies chose to invest heavily “in online business software’, which allows them to keep operating while workers are not in the office. The fact that such software is operated online means that it can “more quickly introduce the latest developments in machine learning and automation”. In a “landmark moment” for the sector, customer-relationship software maker Salesforce became the world’s first software-as-a-service company to enter America’s Dow Jones Industrial Average.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
What’s more, says Dan Gallagher in The Wall Street Journal, while subscription-based software business models are generally popular with investors because of the their “high growth potential” and their “predictability”, Zoom’s “user-friendly service” and “relatively modest” price of $15 a month has also impressed small businesses and consumers, with over a third of revenue now coming from either firms with fewer than ten employees or individuals. Nonetheless, while it’s clear that the service is not a fad, it “remains impossible to know just how many small Zoomers will stay on the service when they no longer have to”.
The firm’s assumption that all new users will stick with the service may prove optimistic, says Richard Waters in the Financial Times. Still, any churn may be balanced by the fact that many of its larger customers are “moving beyond immediate business needs” to make longer-term plans for operating with more remote workers. There are also hopes that it can exploit the fact that many big companies are now considering updating all their communications – including voice systems – to cross-sell other services, helping it become a “full-scale communications company”.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Lloyds axes foreign currency fees for Club Lloyds customers
Club Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
By Daniel Hilton
-
How to invest during stagflation
Trump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
By Dan McEvoy
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves